# A Study of Sigvotatug Vedotin in Advanced Solid Tumors

> **NCT04389632** · PHASE1 · RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 1006 (estimated)

## Conditions studied

- Carcinoma, Non-Small Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- HER2 Negative Breast Neoplasms
- Esophageal Squamous Cell Carcinoma
- Esophageal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Ovarian Neoplasms
- Cutaneous Squamous Cell Cancer
- Exocrine Pancreatic Adenocarcinoma
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
- Stomach Neoplasms

## Interventions

- **DRUG:** sigvotatug vedotin
- **DRUG:** pembrolizumab
- **DRUG:** cisplatin
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT04389632
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-08
- **Primary completion:** 2027-06-16
- **Final completion:** 2029-03-22
- **Target enrollment:** 1006 (ESTIMATED)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04389632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04389632, "A Study of Sigvotatug Vedotin in Advanced Solid Tumors". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04389632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*